Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect

Current cancer immunotherapy [e.g., immune checkpoint blockade (ICB)] only benefits small subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In situ tumor vaccination can reduce TME immunosuppression and thereby improve cancer immunotherapy. Here, we present single-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Furong, Su, Ting, Zhou, Shurong, Liu, Xiang, Yang, Suling, Lin, Shuibin, Guo, Weisheng, Zhu, Guizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348685/
https://www.ncbi.nlm.nih.gov/pubmed/37450588
http://dx.doi.org/10.1126/sciadv.ade6257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348685/
https://www.ncbi.nlm.nih.gov/pubmed/37450588
http://dx.doi.org/10.1126/sciadv.ade6257

Ejemplares similares